A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Sponsor: Pierre Fabre Medicament
Chapel Hill, NC · Charlotte, NC · Durham, NC · +37 more sites